Peptic Ulcer Clinical Trial
Official title:
An Open-label, Multiple-dose, Single-arm, Phase 1 Study to Evaluate the Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
Verified date | February 2017 |
Source | Boryung Pharmaceutical Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers
Status | Completed |
Enrollment | 24 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Healthy subjects between the ages of 19 and 50 at the screening 2. Male subjects whose weight is greater than 55kg Female subjects whose weight is greater than 50kg and within ±20% range of ideal body weight. Ideal body weight(kg) = (Height(cm) - 100) * 0.9 3. For female subjects must show negative for urine pregnancy test and also must meet one of the below listed criteria: - A menopausal woman (Menstruation should stop at least 2 years ago) - Take sterilization operation (Hysterectomy, Ovariotomy, Tubal ligation, any other operation) - Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subject. - Before 3 months of the screening and 1month after the end of drug administration, subjects must meet contraception requirements. - For avoiding the drug-drug interaction, subjects must not use any contraceptive drugs and must choose abstinence or use physical block. 4. A sexually active male subjects must use and accepted method of contraception during the course of the clinical study and must not donate sperms until a month after finishing drug administration. (If male subjects oneself or female partner is sterility, that does not apply.) 5. Subjects who understand the clinical study completely, agree to participate and sign written consent form for conduct precautions Exclusion Criteria: 1. Subjects having liver system disorders, kidney disorders, digestive system disorders, cardiovascular disorders, respiratory disorders, endocrine disorders, neurological disorder or hematological disorders, psychiatric disorders, or a history of malignancy, disorders 2. Subjects having a history of gastrointestinal system disorders influencing drug absorption(i.e, Crohn's disease, ulcer) or surgery (except simple typhlectomy or hernia repair surgery) 3. Subjects having a history of hypersensitivity to additional ingredient or clinically significant hypersensitivity to lafutidine and Irsogladine or any other drug. 4. Subjects who judged for inappropriate to physical examination. ( Disease history, physical examine, vital sign, EKG examine, laboratory examine and so on ). 5. Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption and any other hereditary disorder. 6. Subjects who is sitting after 5minutes break, having Systolic blood pressure = 140 mmHg and Diastolic blood pressure = 90 mmHg, or Systolic blood pressure = 90 mmHg and Diastolic blood pressure = 60 mmHg on vital sign 7. Subjects having a history of drug abuse or positive drug abuse urinalysis testing at screening. 8. Subjects who is pregnancy or feed breast milk. 9. Subjects who has participated in another clinical study before study drug administration Subjects having blood donation within two months or component blood donation within one month before study drug administration 10. Subjects who has drunken beverages caffeine-containing or alcohol or smoking during prohibition period 11. Subjects who has judged to be inappropriate for this study by investigators according to other reasons including clinical lab test result |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | The Catholic University of Korea, Seoul St.Mary's Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Boryung Pharmaceutical Co., Ltd | The Catholic University of Korea |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the plasma concentration versus time curve of Lafutidine and Irsogladine maleate | Sampling time 1, 19, 21days before drug administration, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24hr after drug administration. (total 24times) | ||
Secondary | Peak Plasma Concentration of Lafutidine and Irsogladine | Sampling time 1, 19, 21days before drug administration, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24hr after drug administration. (total 24times) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00471029 -
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
|
Phase 4 | |
Completed |
NCT00152399 -
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
|
Phase 2 | |
Not yet recruiting |
NCT02961296 -
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
|
N/A | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT02342470 -
Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users
|
Phase 2 | |
Completed |
NCT02296021 -
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT00977678 -
Drop in Gastroscopy - Experience After 9 Months
|
N/A | |
Terminated |
NCT04025983 -
Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection
|
N/A | |
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Completed |
NCT05237115 -
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT01667718 -
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
|
Phase 4 | |
Not yet recruiting |
NCT04784910 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
|
Phase 3 | |
Recruiting |
NCT02436018 -
WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
|
N/A | |
Completed |
NCT03367897 -
Bleeding Ulcer and Erosions Study "BLUE Study"
|
||
Active, not recruiting |
NCT02001727 -
HEP-FYN 12-Years Follow-up
|
N/A | |
Completed |
NCT01667692 -
Aizthromycin or Clarithromycin in H-pylori Eradication Regimen
|
Phase 4 | |
Completed |
NCT01376414 -
H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department
|
N/A | |
Completed |
NCT01080326 -
Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
|
N/A | |
Completed |
NCT02536989 -
Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
|
Phase 4 | |
Completed |
NCT00920400 -
Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract
|
N/A |